Current management of symptomatic intracranial stenosis: Medical versus endovascular therapy

被引：16

作者：

Weigele J.B. ^{[1
]}

Taylor R.A. ^{[1
]}

Kasner S.E. ^{[1
]}

机构：

[1] Interventional Neuroradiology Service, Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, PA 19104

来源：

Current Atherosclerosis Reports | 2007年 / 9卷 / 4期

基金：

美国国家卫生研究院;

关键词：

Warfarin; Ischemic Stroke; Cilostazol; Recurrent Stroke; Intracranial Arterial Stenosis;

D O I：

10.1007/s11883-007-0036-1

中图分类号：

学科分类号：

摘要：

Approximately 8% to 10% of all ischemic strokes are caused by intracranial arterial stenosis (IAS). After a stroke or transient ischemic attack due to IAS, patents face a 12% annual risk of recurrent stroke on medical therapy, with most strokes occurring in the first year. Warfarin has been shown to be no better than aspirin in preventing recurrent stokes but poses a higher risk of serious bleeding and death. Groups with the highest risk of recurrent stroke are those with high-grade (≥ 70%) stenosis, those with recent symptom onset, and women. Endovascular treatment of IAS is a rapidly evolving therapeutic option. Antiplatelet agents are currently recommended as the primary treatment for symptomatic IAS, with endovascular therapy reserved for appropriate high-risk cases refractory to medical therapy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：296 / 304

页数：8

共 43 条

[1]

Wityk R.J., Lehman D., Klag M., Et al., Race and sex differences in the distribution of cerebral atherosclerosis, Stroke, 27, pp. 1974-1980, (1996)

[2]

Feldmann E., Daneault N., Kwan E., Et al., Chinese-white differences in the distribution of occlusive cerebrovascular disease, Neurology, 40, pp. 1541-1555, (1990)

[3]

Sacco R.L., Kargman D.E., Gu Q., Et al., Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study, Stroke, 26, pp. 14-20, (1995)

[4]

Chimowitz M.I., Angioplasty or stenting is not appropriate as first-line treatment of intracranial stenosis, Arch Neurol, 58, pp. 1690-1692, (2001)

[5]

Gomez C.R., Orr S.C., Angioplasty and stenting for primary treatment of intracranial arterial stenoses, Arch Neurol, 58, pp. 1687-1690, (2001)

[6]

Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): Study results, Stroke, 35, pp. 1388-1392, (2004)

[7]

Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis, Neuroepidemiology, 22, pp. 106-117, (2003)

[8]

Chimowitz M.I., Kokkinos J., Strong J., Et al., The Warfarin-Aspirin Symptomatic Intracranial. Disease Study, Neurology, 45, pp. 1488-1493, (1995)

[9]

Higashida R.T., Meyers P.M., Connors J.J., Et al., Intracranial angioplasty & stenting for cerebral atherosclerosis: A position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology, J Vasc Interv Radiol, 16, pp. 1281-1285, (2005)

[10]

Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group, N Engl J Med, 313, pp. 1191-1200, (1985)

← 1 2 3 4 5 →